191 related articles for article (PubMed ID: 28900633)
1. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Stemmer SM; Steiner M; Rizel S; Soussan-Gutman L; Ben-Baruch N; Bareket-Samish A; Geffen DB; Nisenbaum B; Isaacs K; Fried G; Rosengarten O; Uziely B; Svedman C; McCullough D; Maddala T; Klang SH; Zidan J; Ryvo L; Kaufman B; Evron E; Karminsky N; Goldberg H; Shak S; Liebermann N
NPJ Breast Cancer; 2017; 3():33. PubMed ID: 28900633
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Stemmer SM; Steiner M; Rizel S; Geffen DB; Nisenbaum B; Peretz T; Soussan-Gutman L; Bareket-Samish A; Isaacs K; Rosengarten O; Fried G; McCullough D; Svedman C; Shak S; Liebermann N; Ben-Baruch N
NPJ Breast Cancer; 2017; 3():32. PubMed ID: 28900632
[TBL] [Abstract][Full Text] [Related]
3. Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Stemmer SM; Steiner M; Rizel S; Ben-Baruch N; Uziely B; Jakubowski DM; Baron J; Shak S; Soussan-Gutman L; Bareket-Samish A; Fried G; Rosengarten O; Itay A; Nisenbaum B; Katz D; Leviov M; Tokar M; Liebermann N; Geffen DB
NPJ Breast Cancer; 2019; 5():41. PubMed ID: 31728408
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW
JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
[TBL] [Abstract][Full Text] [Related]
6. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
Sparano JA; Crager MR; Tang G; Gray RJ; Stemmer SM; Shak S
J Clin Oncol; 2021 Feb; 39(6):557-564. PubMed ID: 33306425
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
9. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
Berdunov V; Millen S; Paramore A; Griffin J; Reynia S; Fryer N; Brown R; Longworth L
Clinicoecon Outcomes Res; 2022; 14():619-633. PubMed ID: 36157054
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Sparano JA; Gray RJ; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Ravdin PM; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
N Engl J Med; 2018 Jul; 379(2):111-121. PubMed ID: 29860917
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study.
Rotem O; Peretz I; Leviov M; Kuchuk I; Itay A; Tokar M; Paluch-Shimon S; Maimon O; Yerushalmi R; Drumea K; Evron E; Sonnenblick A; Gal-Yam E; Goldvaser H; Samih Y; Merose R; Bareket-Samish A; Soussan-Gutman L; Stemmer SM
NPJ Breast Cancer; 2023 Jun; 9(1):49. PubMed ID: 37268607
[TBL] [Abstract][Full Text] [Related]
13. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
[TBL] [Abstract][Full Text] [Related]
15. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
[TBL] [Abstract][Full Text] [Related]
16. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
17. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
[TBL] [Abstract][Full Text] [Related]
18. Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer.
Zhu L; Ma N; Wang B; Zhou C; Yan Y; Wang K; He J; Ren Y
Oncol Lett; 2019 Jun; 17(6):5469-5480. PubMed ID: 31186766
[TBL] [Abstract][Full Text] [Related]
19. Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer.
Jayasekera J; Sparano JA; Gray R; Isaacs C; Kurian A; O'Neill S; Schechter CB; Mandelblatt J
JNCI Cancer Spectr; 2019 Dec; 3(4):pkz062. PubMed ID: 32337487
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
